April 13, 2023 7:42am
So, what’s different – what lies ahead more hesitancy, turning or burning?
Always’ remember and do NOT forget, today’s investors’ gold is a trader’s disposable tin.
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
The 8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday …
Dow futures are UP +0.02% or (+6 points), S&P futures are UP +0.11% or (+4 point) and NASDAQ futures are UP +0.28% or (+36 points) early in the pre-open – so far
Stock futures rose slightly Thursday,
European markets were mixed,
Asia Pacific markets mostly fall
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes rose and then split to the downside on Wednesday after the release of cooler-than-expected CPI data as the Dow closed DOWN -38.29 points (-0.11%), the S&P closed DOWN -16.99 points (-0.41%) while the Nasdaq closed DOWN -102.54 points (-0.85%).
Economic Data Docket: producer price index (PPI) report from the Bureau of Labor Statistics due out at 8:30 a.m. ET
· Weekly jobless claims are also due.
Wednesday’s (4/12) … RegMed Investors’ (RMi) closing bell: “CPI, a cooled rise of 0.1% in March. Tight ranges, stunted sentiment, lethargic direction and wanting confidence inhabit the cell and gene therapy sector triggering the sector’s trip and fall.” … https://www.regmedinvestors.com/articles/12912
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … “The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth” … https://www.regmedinvestors.com/articles/12843 --- 31 of 35 (my coverage group)
Ebb and flow:
Q2/23 – 1 holiday, 2 positive close and 5 negative closes
Q1/23 –
· March – ended with 10 positive and 13 negative closes
· February – 1 holiday, 2 vacation, 7 negative and 8 positive closes
· January – 2 holidays, 11 positive and 9 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
I’m NOT betting in today’s lottery … the house almost always wins.
The BOTTOM LINE: I try to keep it simple and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
Which way will PPI go today – what’s flashing, BUY or SELL – I say there is a “matter” for BOTH?
“Investor sentiment readings are regarded as contrarian indicators because the more bullish that people say they are, the presumption goes, the less money there is on the sidelines available to buy stock. Conversely, the more bearish investors say they are, the more likely they are to have already sold”. <CNBC>
Reiterating, “A SUSTAINABLE uptrend is needed to get credibility BACK into the sector’s investment”
I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product.
And I can always be WRONG but, I am mostly EARLY!
Also, the rush of Q4 and FY22 earnings to release is slowing …
· 31 of my 35 covered have reported - 4 remaining
· Waiting for remaining release announcements …
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
